CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Eli Lilly and Company

LLY
$1.09TMega Cap

Next catalyst

Phase 2December 2026

Abemaciclib

Breast Cancer

Get an email about LLY's next catalysts

Track Eli Lilly and Company (LLY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 28 more upcoming events in our data (Phase 2 readout, company event, Phase 3 readout).See the timeline

Catalyst Timeline

29 upcoming, 5 past

Phase 2Next

Abemaciclib Phase 2 Est. Readout

December 2026~Abemaciclib53

Estimated primary completion for Abemaciclib trial (NCT04393285) in Endometrial Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

Necitumumab Phase 2 Est. Readout

December 2026~Necitumumab30

Estimated primary completion for Necitumumab trial (NCT04285671) in Metastatic Lung Non-Small Cell Carcinoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide Phase 2 Est. Readout

December 2026~Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide18

Estimated primary completion for Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide trial (NCT01025089) in Thymoma. Topline data typically follows completion by weeks to months.

Source
Other

Other

January 2027~

Centessa Pharmaceuticals announced a CEO transition with president Mario Alberto Accardi set to assume the top role on January 1, 2027, replacing Saurabh Saha. The company is also appointing a new CMO for a cardiovascular program led by John Maraganore and Clive Meanwell.

Phase 2

Brenipatide Phase 2 Est. Readout (RENEW-Smk-1)

February 2027~Brenipatide222

Primary completion for Brenipatide trial (NCT07223840) in Smoking

Source
Phase 2

Pirtobrutinib Phase 2 Est. Readout

February 2027~Pirtobrutinib50

Estimated primary completion for Pirtobrutinib trial (NCT06522386) in Mantle Cell Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Solbinsiran Phase 2 Est. Readout (SOLARIS-1)

March 2027~Solbinsiran60

Estimated primary completion for Solbinsiran trial (NCT07269210) in Severe Hypertriglyceridemia. Topline data typically follows completion by weeks to months.

Source
Phase 2

Niraparib Tosylate Monohydrate Phase 2 Est. Readout (NICHOL)

March 2027~Niraparib Tosylate Monohydrate73

Estimated primary completion for Niraparib Tosylate Monohydrate trial (NCT06594679) in Ovarian Cancer. Topline data typically follows completion by weeks to months.

Source

How LLY's past catalysts played out

Market Overview

Stock performance and key metrics

NYSEPharmaceutical PreparationsPharmaceutical🇺🇸North AmericaINDIANAPOLIS50.0K employees

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Website
Drug Pipeline

Remternetug (SC)

Phase 3

Alzheimer's Disease

Retatrutide

Phase 3

Obesity

Ultra-Rapid Lispro

Phase 3

Type 1 Diabetes Mellitus

LY2216684

Phase 3

Major Depressive Disorder

Insulin Efsitora Alfa

Phase 3

Type 2 Diabetes

Abemaciclib

Phase 3

Breast Cancer

Patent 2039

LY3819253

Phase 3

COVID-19

LY900014

Phase 3

Type 1 Diabetes Mellitus

Ixekizumab Auto-Injector

Phase 3

Plaque Psoriasis

GEMZAR

Phase 3

Pancreatic Neoplasms

Dulaglutide

Phase 3

Type 2 Diabetes Mellitus

LY2605541

Phase 3

Type 1 Diabetes Mellitus

Baricitinib

Phase 3

Systemic Juvenile Idiopathic Arthritis

Patent 2032

Galcanezumab

Phase 3

Chronic Migraine

Ixekizumab

Phase 3

Psoriasis

Tirzepatide

Phase 3

Overweight

Patent 2041

Remternetug (IV)

Phase 3

Alzheimer's Disease

LY353381

Phase 3

Breast Neoplasms

Insulin Peglispro

Phase 3

Type 2 Diabetes Mellitus

teriparatide

Phase 3

Osteoporosis, Postmenopausal

Insulin Lispro

Phase 3

Type 2 Diabetes Mellitus

Paclitaxel (Taxane)

Phase 3

Non-Small-Cell Lung Carcinoma

Patent 2034

Human Insulin Inhalation Powder

Phase 3

Diabetes Mellitus, Type 2

Detemir

Phase 3

Diabetes Mellitus Type 2

tadalafil once a day [T(OaD)]

Phase 3

Erectile Dysfunction

Etanercept

Phase 3

Plaque Psoriasis

Insulin Degludec

Phase 3

Type 2 Diabetes Mellitus

Insulin lispro mix 25

Phase 3

Diabetes Mellitus Type 2

cDMARD

Phase 3

Rheumatoid Arthritis

LY2963016

Phase 3

Type 1 Diabetes

[Lu-177]-PNT2002

Phase 3

Metastatic Castration-Resistant Prostate Cancer

LY2062430

Phase 3

Alzheimer's Disease

liposomal doxorubicin

Phase 3

Genital Neoplasms, Female

BEC2 Vaccine

Phase 3

Carcinoma, Small Cell Lung

Lebrikizumab

Phase 3

Atopic Dermatitis

LY3537982

Phase 3

Carcinoma, Non-Small-Cell Lung

amantadine

Phase 3

Schizophrenia

venlafaxine

Phase 3

Anxiety Disorders

Necitumumab

Phase 3

Solid Tumors

enzastaurin

Phase 3

Non-Small Cell Lung Cancer

Tadalafil

Phase 3

Benign Prostatic Hyperplasia

Methylphenidate

Phase 3

Attention Deficit Hyperactivity Disorder

Glargine

Phase 3

Diabetes Mellitus, Type 1

lithium

Phase 3

Manic or Mixed Episode Associated With Bipolar I Disorder

Donanemab

Phase 3

Alzheimer Disease

Imlunestrant

Phase 3

Breast Neoplasms

Insulin Lispro Protamine Suspension

Phase 3

Diabetes Mellitus, Type 2

Somatropin

Phase 3

Growth Hormone Deficiency

Nasal Glucagon

Phase 3

Hypoglycemia

Lasmiditan

Phase 3

Migraine

Oral antihyperglycemics

Phase 3

Diabetes Mellitus

BI 10773/BI 1356

Phase 3

Diabetes Mellitus, Type 2

Raloxifene

Phase 3

Vasomotor Symptoms

Tirzepatide Dose 1

Phase 3

Type2 Diabetes

Intramuscular Glucagon

Phase 3

Diabetes Mellitus, Type 1

Oral Antihyperglycemic Medications (OAMs)

Phase 3

Type 2 Diabetes Mellitus

Insulin Lispro 6 Day (6D)

Phase 3

Diabetes Mellitus, Type 1

Remternetug

Phase 3

Alzheimer's Disease

Fluoxetine

Phase 3

Major Depressive Disorder

Orforglipron

Phase 3

Obesity

Methylphenidate Hydrochloride

Phase 3

Attention Deficit Hyperactivity Disorder

gemcitabine hydrochloride

Phase 3

Breast Cancer

Insulin Lispro Protamine Suspension (ILPS)

Phase 3

Diabetes Mellitus, Type 2

Human Insulin NPH

Phase 3

Diabetes Mellitus, Type 2

Drotrecogin alfa (activated)

Phase 3

Sepsis

Salmon Calcitonin

Phase 3

Osteoporosis

LY3537031

Phase 3

Alcohol Use Disorder

Risedronate

Phase 3

Osteoporosis

LY4064809

Phase 3

Breast Neoplasms

Topical corticosteroid

Phase 3

Atopic Dermatitis

Olomorasib

Phase 3

Carcinoma, Non-Small-Cell Lung

Insulin lispro 2 day reservoir in-use

Phase 3

Diabetes Mellitus, Type 1

teriparatide 20 micrograms/day subcutaneous

Phase 3

Osteoporosis, Post-Menopausal

Nasal Glucagon (NG)

Phase 3

Drug-specific Antibodies

Standard therapy for INCS

Phase 3

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Lantus

Phase 3

Diabetes Mellitus, Type 2

Neutral protamine hagedorn insulin

Phase 3

Diabetes Mellitus, Type 2

Ethinyl estradiol

Phase 3

Turner Syndrome

dirucotide

Phase 3

Secondary Progressive Multiple Sclerosis

Insulin Aspart

Phase 3

Type 2 Diabetes Mellitus

Ramucirumab DP (IMC-1121B)

Phase 3

Hepatocellular Carcinoma

Injectable insulin

Phase 3

Diabetes Mellitus, Type 2

ixekizumab Dosing Regimen

Phase 3

Psoriasis

SSRI

Phase 3

Major Depressive Disorder

leuprorelin

Phase 3

Idiopathic Short Stature (ISS)

Sofetabart Mipitecan

Phase 3

Ovarian Neoplasms

Atomoxetine

Phase 3

Attention Deficit Hyperactivity Disorder

Pemetrexed

Phase 3

Non-small Cell Lung Cancer

Somatropin (rDNA origin) for injection

Phase 3

Failure to Thrive

LY3650150

Phase 3

Perennial Allergic Rhinitis (PAR)

LY2189265

Phase 3

Diabetes Mellitus, Type 2

Sulfonylureas (SU)

Phase 3

Type 2 Diabetes Mellitus

LY2127399

Phase 3

Arthritis, Rheumatoid

Testosterone Solution

Phase 3

Hypogonadism

Folinic acid

Phase 3

Colorectal Carcinoma

Arzoxifene

Phase 3

Osteoporosis, Postmenopausal

Mirikizumab

Phase 3

Ulcerative Colitis

Etesevimab

Phase 3

COVID-19

Human regular U-500 insulin (CSII)

Phase 3

Type 2 Diabetes Mellitus

Tanezumab

Phase 3

Osteoarthritis, Hip

Oral Antihyperglycemic Medication

Phase 3

Diabetes Mellitus, Type 2

Intramuscular olanzapine depot

Phase 3

Schizophrenic Disorders

Pegilodecakin

Phase 3

Pancreatic Cancer

Secukinumab

Phase 3

Psoriasis

LY900003

Phase 3

Carcinoma, Non-Small-Cell Lung

Paroxetine

Phase 3

Major Depressive Disorder

Galunisertib

Phase 3

Glioblastoma

Humalog Mix 50

Phase 3

Diabetes Mellitus, Type 1

Aducanumab

Phase 3

Mild Cognitive Impairment (MCI)

LY2216684 (edivoxetine)

Phase 3

Depressive Disorder, Major

simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder

Phase 3

Diabetes Mellitus, Type 2

Rapid-Acting Intramuscular Olanzapine

Phase 3

Schizophrenia

Biguanides (BG)

Phase 3

Type 2 Diabetes Mellitus

Exenatide

Phase 3

Diabetes Mellitus, Type 2

Biguanide (BG)

Phase 3

Type 2 Diabetes Mellitus

semagacestat

Phase 3

Alzheimer's Disease

LY450139

Phase 3

Alzheimer's Disease

Vepugratinib

Phase 3

Carcinoma, Transitional Cell

LANTUS®

Phase 3

Diabetes Mellitus, Type 2

SGLT2 inhibitor

Phase 3

Type 2 Diabetes Mellitus

Ruboxistaurin mesylate

Phase 3

Diabetic Neuropathies

solanezumab

Phase 3

Alzheimer's Disease

Finasteride

Phase 3

Benign Prostatic Hyperplasia

Glucagon Nasal Powder

Phase 3

Diabetes Mellitus

Standard Adjuvant Endocrine Therapy

Phase 3

Breast Cancer

Alendronate Sodium

Phase 3

Osteoporosis

Oral antihyperglycemic medication (OAM)

Phase 3

Type 2 Diabetes Mellitus

Muvalaplin

Phase 3

Elevated Lp(a)

Tamsulosin

Phase 3

Benign Prostatic Hyperplasia

Ixekizumab Dosing Regimens 1, 2, and 3

Phase 3

Psoriasis

insulin lispro injection Low Mix

Phase 3

Type 2 Diabetes Mellitus

Ramucirumab (IMC-1211B) DP

Phase 3

Gastric Cancer

Prasugrel

Phase 3

Sickle Cell Anemia

Commercially-available Aspirin

Phase 3

Acute Coronary Syndrome

Lepodisiran Sodium

Phase 3

Atherosclerotic Cardiovascular Disease (ASCVD)

Fumaric Acid Esters

Phase 3

Plaque Psoriasis

Testosterone MD-Lotion

Phase 3

Hypogonadism

Raloxifene HCL

Phase 3

Osteoporosis, Postmenopausal

Calcium Supplement

Phase 3

Osteoporosis, Postmenopausal

Eloralintide

Phase 3

Overweight

Duloxetine Hydrochloride (HCI)

Phase 3

Multiple Sclerosis

somatropin, rDNA origin, for injection

Phase 3

Growth Disorder

OAMs

Phase 3

Diabetes Mellitus, Type 2

salmon calcitonin subcutaneous

Phase 3

Osteoporosis, Post-Menopausal

Ramucirumab (IMC-1121B)

Phase 3

Breast Cancer

Lebrikizumab Pen

Phase 3

Atopic Dermatitis

5-Fluorouracil

Phase 3

Head and Neck Cancer

Cetuximab

Phase 3

Ovarian Cancer

Selpercatinib

Phase 3

Non-Small Cell Lung Cancer

ERA as specific PAH treatment

Phase 3

Hypertension, Pulmonary

Escitalopram

Phase 3

Major Depressive Disorder

Haloperidol

Phase 3

Schizophrenia

Mirikizumab SC

Phase 3

Ulcerative Colitis

Insulin Lispro (U100)

Phase 3

Type 2 Diabetes

Duloxetine hydrochloride

Phase 3

Diabetic Neuropathy, Painful

injected insulin

Phase 3

Diabetes Mellitus

Ruboxistaurin

Phase 3

Type 1 Diabetes Mellitus

Olanzapine and Fluoxetine combination (OFC)

Phase 3

Treatment Resistant Depression

high dose FDC

Phase 3

Diabetes Mellitus, Type 2

Brenipatide

Phase 3

Asthma

BI 10773 low dose

Phase 3

Diabetes Mellitus, Type 2

low dose FDC

Phase 3

Diabetes Mellitus, Type 2

calcitonin subcutaneous

Phase 3

Osteoporosis, Post-Menopausal

cleminorexton

Phase 3

Narcolepsy Type 1

Insulin Levemir

Phase 3

Diabetes Mellitus, Type 1

Bamlanivimab

Phase 3

COVID-19

Mirikizumab IV

Phase 3

Ulcerative Colitis

Olaratumab

Phase 3

Metastatic Pancreatic Cancer

Pirtobrutinib

Phase 3

Lymphoma, Non-Hodgkin

Olanzapine Hydrochloride

Phase 3

Bipolar Disorder

Other standard therapy for ADHD

Phase 3

Attention Deficit Hyperactivity Disorder

Linagliptin/Pioglitazone FDC

Phase 3

Diabetes Mellitus, Type 2

Lepodisiran

Phase 3

Atherosclerosis

BI 10773

Phase 3

Diabetes Mellitus, Type 2

TAS 102

Phase 3

Colorectal Cancer

Linagliptin

Phase 3

Diabetes Mellitus, Type 2

Intracoronary infusion of enriched bone marrow-derived progenitor cells

Phase 3

Myocardial Infarction

Sulfonylureas

Phase 3

Type 2 Diabetes Mellitus

Docetaxel (Taxane)

Phase 3

Non-Small-Cell Lung Carcinoma

valproate

Phase 3

Manic or Mixed Episode Associated With Bipolar I Disorder

Insulin lispro 6 day reservoir in-use

Phase 3

Diabetes Mellitus, Type 1

alpha-glucosidase inhibitor (a-GI)

Phase 3

Type 2 Diabetes Mellitus

Empagliflozin low dose qd

Phase 3

Diabetes Mellitus, Type 2

Glinides

Phase 3

Type 2 Diabetes Mellitus

Empagliflozin low dose bid

Phase 3

Diabetes Mellitus, Type 2

fibrinolytic therapy or combination reduced fibrinolytic therapy

Phase 3

Myocardial Infarction

Empagliflozin high dose qd

Phase 3

Diabetes Mellitus, Type 2

Empagliflozin high dose bid

Phase 3

Diabetes Mellitus, Type 2

Topical Corticosteroid (TCS)

Phase 3

Atopic Dermatitis

Empagliflozin + Linagliptin

Phase 3

Diabetes Mellitus, Type 2

BI 10773 open label

Phase 3

Diabetes Mellitus, Type 2

BI10773

Phase 3

Diabetes Mellitus, Type 2

Ixekizumab Prefilled Syringe

Phase 3

Plaque Psoriasis

Atomoxetine Hydrochloride

Phase 3

Attention Deficit Hyperactivity Disorder

Erbitux (Cetuximab)

Phase 2

Colorectal Neoplasms

LY3295668

Phase 2

Neoplasms

LY2523355

Phase 2

Metastatic Breast Cancer

Sivelestat

Phase 2

Respiratory Distress Syndrome, Adult

Icrucumab

Phase 2

Colon Cancer

LY2140023

Phase 2

Schizophrenia

LY3209590

Phase 2

Type 2 Diabetes Mellitus

Empagliflozin low

Phase 2

Diabetes Mellitus, Type 1

cetuximab (Erbitux ®)

Phase 2

Head and Neck Cancer

Herceptin

Phase 2

Breast Cancer

Enzastaurin Hydrochloride

Phase 2

Breast Neoplasms

Pemetrexed - Phase 1

Phase 2

Ovarian Cancer

IMC-1121B (ramucirumab)

Phase 2

Carcinoma, Non-Small-Cell Lung

LY3041658

Phase 2

Hidradenitis Suppurativa

Ipatasertib

Phase 2

Endometrial Cancer

LY4268989

Phase 2

Ulcerative Colitis

LY4100511

Phase 2

Plaque Psoriasis

Inavolisib

Phase 2

Endometrial Cancer

Pemetrexed - Before Protocol Amendment

Phase 2

Non Small Cell Lung Cancer

LY3016859

Phase 2

Osteoarthritis

LY2484595

Phase 2

Dyslipidemia

MORF-057

Phase 2

Inflammatory Bowel Diseases

DC-806

Phase 2

Plaque Psoriasis

Carboplatin, Pemetrexed and Bevacizumab

Phase 2

Non Small Cell Lung Cancer

Granulocyte colony-stimulating factor (G-CSF)

Phase 2

Small Cell Lung Cancer

Prexasertib

Phase 2

Ovarian Cancer

LY2409021

Phase 2

Diabetes Mellitus, Type 2

avastin

Phase 2

Colorectal Cancer

Hydroxychloroquine Sulfate

Phase 2

Pancreatic Cancer

LY3473329

Phase 2

Lipoprotein Disorder

LY517717

Phase 2

Total Knee Replacement

LY3857210

Phase 2

Diabetic Peripheral Neuropathic Pain

LY2951742

Phase 2

Migraine Headache

Enzyme-inducing antiepileptic drugs (EIAED)

Phase 2

Recurrent Glioblastoma

Cixutumumab

Phase 2

Non-Small-Cell Lung Carcinoma

Mitoxantrone

Phase 2

Prostate Cancer

Folate

Phase 2

Non-small Cell Lung Cancer (NSCLC)

LY4005130

Phase 2

Vitiligo

Carboplatin (AUC 6)

Phase 2

Carcinoma, Non-Small-Cell Lung

LY4395089

Phase 2

Crohn Disease

LY2189102

Phase 2

Arthritis, Rheumatoid

Doxorubicin (Adriamycin)

Phase 2

Hodgkin's Disease

LY3451838

Phase 2

Migraine

Taltz

Phase 2

Idiopathic Subglottic Stenosis

Non-enzyme inducing antiepileptic drugs (NEIAED)

Phase 2

Recurrent Glioblastoma

LY2422347

Phase 2

Sleep Initiation and Maintenance Disorders

Platinol

Phase 2

Carcinoma, Transitional Cell

LY4065967

Phase 2

Diabetic Peripheral Neuropathic Pain

LY2623091

Phase 2

Primary Hypertension

LY3938577

Phase 2

Diabetes Mellitus, Type 2

Mirikizumab - Intravenous (IV)

Phase 2

Crohn Disease

LY2428757

Phase 2

Diabetes Mellitus, Type 2

LOXO-292

Phase 2

Medullary Thyroid Cancer

Tadalafil- Tablet or Oral suspension

Phase 2

Pulmonary Arterial Hypertension

LY3023414

Phase 2

Prostate Cancer Metastatic

Pemetrexed - After Protocol Amendment

Phase 2

Non Small Cell Lung Cancer

Enzastaurin HCL

Phase 2

Non-Small-Cell Lung Carcinoma

IMC-A12

Phase 2

Prostate Cancer

Mirikizumab - Subcutaneous (SC)

Phase 2

Crohn Disease

LY3561774

Phase 2

Dyslipidemias

LY3848575

Phase 2

Neuropathic Pain

Mevidalen

Phase 2

Alzheimer Disease

ALIMTA

Phase 2

Colorectal Cancer

Bimagrumab

Phase 2

Obesity

LY2603618

Phase 2

Non Small Cell Lung Cancer

BI 10773 high dose

Phase 2

Diabetes Mellitus, Type 2

LY2439821

Phase 2

Rheumatoid Arthritis

human insulin inhalation powder (HIIP)

Phase 2

Diabetes Mellitus, Type 1

LY3457263

Phase 2

Type 2 Diabetes

Emibetuzumab

Phase 2

Carcinoma, Non-Small-Cell Lung

Testosterone

Phase 2

Ejaculatory Dysfunction

LY3214996

Phase 2

Pancreatic Cancer

Solbinsiran

Phase 2

Severe Hypertriglyceridemia

Cetuximab + platinum + gemcitabine

Phase 2

Non-Small-Cell Lung Carcinoma

Prophylactic Loperamide

Phase 2

Metastatic Breast Cancer

Dinutuximab

Phase 2

Relapsed Solid Tumor

Ramucirumab DP

Phase 2

Carcinoma of Urinary Tract

LY451395

Phase 2

Alzheimer's Disease

Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

Phase 2

Thymoma

LY3016859 ISA

Phase 2

Osteoarthritis, Knee

LOXO-305

Phase 2

Leukemia, Lymphoid

LY317615

Phase 2

Non-Hodgkin's Lymphoma

LY2181308 sodium

Phase 2

Prostate Cancer

LY3819469

Phase 2

Lipoprotein Disorder

LY686017

Phase 2

Social Phobia

LY573636-sodium

Phase 2

Ovarian Cancer

Zagotenemab

Phase 2

Alzheimer Disease (AD)

Enzastaurin 500 milligram (mg) Once Daily (QD)

Phase 2

Glioblastoma Multiforme

STX-478

Phase 2

Breast Cancer

naveglitazar

Phase 2

Diabetes Mellitus, Non-Insulin-Dependent

Mazdutide

Phase 2

Alcohol Use Disorder

Macupatide

Phase 2

Obesity

LY2452473

Phase 2

Erectile Dysfunction

LY3305677

Phase 2

Obesity

LY2875358

Phase 2

Carcinoma, Non-Small-Cell Lung

LY450139 dihydrate

Phase 2

Alzheimer's Disease

Merestinib

Phase 2

Biliary Tract Cancer

Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)

Phase 2

Carcinoma, Non-Small-Cell Lung

IMC-11F8 (necitumumab)

Phase 2

Metastatic Colorectal Cancer

U-500 insulin, 200 syringe units

Phase 2

Type 2 Diabetes

LY2196044

Phase 2

Alcohol Dependence

LY3009104

Phase 2

Arthritis, Rheumatoid

Drotrecogin alfa activated (Xigris)

Phase 2

End Stage Renal Disease

Baricitinib 4 milligram Oral Tablet

Phase 2

Lichen Planus, Oral

IMC-A12 (Cixutumumab)

Phase 2

Adenocarcinoma of the Prostate

LY2090314

Phase 2

Leukemia

Eltrekibart

Phase 2

Hidradenitis Suppurativa

Lutetium Lu 177-PSMA-617

Phase 2

Castration-Resistant Prostate Carcinoma

5FU/folinic acid

Phase 2

Colorectal Cancer

Empagliflozin medium

Phase 2

Diabetes Mellitus, Type 1

LY3541860

Phase 2

Rheumatoid Arthritis

5 - Fluorouracil

Phase 2

Solid Tumor

Leucovorin (LV)

Phase 2

Colorectal Cancer

Pemetrexed Phase 1

Phase 2

Non-Small Cell Lung Cancer

LY3537021

Phase 2

Nausea

Lutetium Lu-177 PNT2002

Phase 2

Oligometastatic Prostate Carcinoma

LY3462817

Phase 2

Rheumatoid Arthritis

Exenatide/min

Phase 2

Euglycemia

carboplatin and gemcitabine

Phase 2

Non Small Cell Lung Cancer

LY3015014

Phase 2

Hypercholesterolemia

LY2624803

Phase 2

Primary Insomnia

Vitamin B12

Phase 2

Non Small Cell Lung Cancer

LY041001 (HIIP)

Phase 2

Diabetes Mellitus, Type 2

IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)

Phase 2

Hepatocellular Carcinoma

Mibavademab

Phase 2

Obesity

LY3972406

Phase 2

Plaque Psoriasis

LY3372689

Phase 2

Alzheimer Disease

Selpercatinib Monotherapy

Phase 2

Differentiated Thyroid Cancer

Empagliflozin high

Phase 2

Diabetes Mellitus, Type 1

Carboplatin - Phase 2

Phase 2

Ovarian Cancer

LY3841136

Phase 2

Obesity

Gemcitabine, Etoposide

Phase 2

Pancreatic Cancer

LY3039478

Phase 2

T-cell Acute Lymphoblastic Leukemia

LY3437943

Phase 2

Obesity

LY2510924

Phase 2

Extensive Stage Small Cell Lung Carcinoma

ORX750

Phase 2

Narcolepsy Type 1

LY293111

Phase 2

Pancreatic Cancer

LY2828360

Phase 2

Osteoarthritis, Knee

LY3023703

Phase 2

Acute Pain

pegfilgrastim

Phase 2

Ovarian Cancer

LY2189265 and Lifestyle Measures

Phase 2

Diabetes Mellitus, Type 2

Cetuximab in combination with Carboplatin/Gemcitabine

Phase 2

Stage IV Non-Small Cell Lung Cancer

LY518674

Phase 2

Metabolic Syndrome X

Prasugrel (CS-747)

Phase 2

Cardiovascular Diseases

sPLA2 Inhibitor

Phase 2

Sepsis

LY3526318

Phase 2

Chronic Low-back Pain

Mazisotine

Phase 2

Diabetic Peripheral Neuropathy

LY2495655

Phase 2

Pancreatic Cancer

U-500 insulin, 100 syringe units

Phase 2

Type 2 Diabetes

IMC-1121B

Phase 2

Cancer

Transdermal Teriparatide

Phase 2

Osteoporosis

Galcanezumab Prefilled Syringe

Phase 2

Vestibular Migraine

Carboplatin - Phase 1

Phase 2

Ovarian Cancer

LY3202626

Phase 2

Alzheimer Disease

IMC-18F1

Phase 2

Breast Cancer

PPAR alpha

Phase 2

Hypercholesterolemia

5 - FU

Phase 2

Solid Tumor

Folinic acid (FA)

Phase 2

Metastatic Colorectal Cancer

gemcitabine, folinic acid, 5-FU

Phase 2

Metastatic Pancreatic Cancer

Buprenorphine

Phase 2

Opioid Use Disorder

LY3549492

Phase 2

Obesity

LY3154207

Phase 2

Lewy Body Dementia

Niraparib Tosylate Monohydrate

Phase 2

Ovarian Cancer

arzoxifene hydrochloride

Phase 2

Endometrial Cancer

Eplerenone

Phase 2

Chronic Kidney Disease

Triamcinolone (Optional)

Phase 2

Atopic Dermatitis

depot octreotide

Phase 2

Carcinoma

Subcutaneous Teriparatide

Phase 2

Osteoporosis

LY3556050

Phase 2

Diabetic Peripheral Neuropathy

Pemetrexed - Phase 2

Phase 2

Ovarian Cancer

ALIMTA plus Epirubicin

Phase 2

Breast Cancer

Fulvestrant Run-In

Phase 2

ER-Positive Breast Cancer

LY3871801

Phase 2

Rheumatoid Arthritis

LY2157299

Phase 2

Hepatocellular Carcinoma

LY2181308

Phase 2

Non-small Cell Lung Cancer

tasisulam

Phase 2

Metastatic Melanoma

Giredestrant

Phase 2

Endometrial Cancer

LY2784544

Phase 2

Neoplasms, Hematologic

LY3502970

Phase 2

Obesity

LY2541546

Phase 2

Osteoporosis

S-1

Phase 2

Metastatic Gastric Adenocarcinoma

LY2228820

Phase 2

Epithelial Ovarian Cancer

mitomycin C

Phase 2

Superficial Bladder Cancer

empagliflozin low dose

Phase 2

Diabetes Mellitus, Type 1

LY545694

Phase 2

Osteoarthritis Knee Pain

empagliflozin medium dose

Phase 2

Diabetes Mellitus, Type 1

Brexucabtagene Autoleucel

Phase 2

Mantle Cell Lymphoma

empagliflozin high dose

Phase 2

Diabetes Mellitus, Type 1

Platinum + Gemcitabine

Phase 2

Non-Small-Cell Lung Carcinoma

Radiation

Phase 2

Glioma

Diabetes Mellitus, Type 2

6 drugs in this indication

Type 2 Diabetes Mellitus

5 drugs in this indication

Type 2 Diabetes

5 drugs in this indication

Obesity

5 drugs in this indication

Alzheimer's disease

4 drugs in this indication

Psoriasis

3 drugs in this indication

Type 1 Diabetes Mellitus

3 drugs in this indication

diabetes

3 drugs in this indication

Non-Small-Cell Lung Carcinoma

2 drugs in this indication

Attention Deficit Hyperactivity Disorder

2 drugs in this indication

Plaque Psoriasis

2 drugs in this indication

Alzheimer's disease diagnostic

2 drugs in this indication

weight loss/obesity

2 drugs in this indication

Weight loss

2 drugs in this indication

reduce cardiovascular risk in adults with type 2 diabetes

2 drugs in this indication

Growth Disorder

1 drug in this indication

Benign Prostatic Hyperplasia

1 drug in this indication

Asthma

1 drug in this indication

Colorectal Neoplasms

1 drug in this indication

COVID-19

1 drug in this indication

Systemic Juvenile Idiopathic Arthritis

1 drug in this indication

Ovarian Cancer

1 drug in this indication

diabetes and obesity

1 drug in this indication

Pancreatic Neoplasms

1 drug in this indication

Overweight

1 drug in this indication

Sickle Cell Anemia

1 drug in this indication

Breast Cancer

1 drug in this indication

Schizophrenia

1 drug in this indication

Carcinoma, Non-Small-Cell Lung

1 drug in this indication

Major Depressive Disorder

1 drug in this indication

Total Knee Replacement

1 drug in this indication

Diabetic Peripheral Neuropathic Pain

1 drug in this indication

Metastatic Pancreatic Cancer

1 drug in this indication

Chronic Migraine

1 drug in this indication

Erectile Dysfunction

1 drug in this indication

Type 1 Diabetes

1 drug in this indication

Arthritis, Rheumatoid

1 drug in this indication

Neoplasms, Hematologic

1 drug in this indication

Lipoprotein Disorder

1 drug in this indication

Rheumatoid Arthritis

1 drug in this indication

Migraine

1 drug in this indication

Rare genetic forms of obesity

1 drug in this indication

treatment-resistant depression

1 drug in this indication

melanoma

1 drug in this indication

infectious disease

1 drug in this indication

Infectious diseases

1 drug in this indication

Osteoarthritis

1 drug in this indication

Inflammatory Bowel Diseases

1 drug in this indication

metastatic breast cancer

1 drug in this indication

cancer

1 drug in this indication

cardiometabolic

1 drug in this indication

Acute Pain

1 drug in this indication

Coronary Artery Disease

1 drug in this indication

previously untreated CLL/SLL

1 drug in this indication

Obesity, Type 2 Diabetes

1 drug in this indication

Previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in adult patients

1 drug in this indication

weight loss in people with heart disease

1 drug in this indication

obesity, type 2 diabetes, cardiovascular disease

1 drug in this indication

to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes

1 drug in this indication

cardiovascular risk reduction

1 drug in this indication

Metastatic Castration-Resistant Prostate Cancer

1 drug in this indication

autoimmune

1 drug in this indication

severe alopecia areata in pediatric patients 12 years of age and older

1 drug in this indication

reduce risk of major cardiovascular events

1 drug in this indication

diabetes, cardiometabolic conditions, leukemia

1 drug in this indication

Carcinoma, Transitional Cell

1 drug in this indication

type 2 diabetes in adults

1 drug in this indication

alopecia (children 12 and up)

1 drug in this indication

Breast Neoplasms

1 drug in this indication

Substance and psychiatric disorders

1 drug in this indication

Primary Hypertension

1 drug in this indication

Pulmonary Arterial Hypertension

1 drug in this indication

Prostate Cancer Metastatic

1 drug in this indication

Carcinoma, Small Cell Lung

1 drug in this indication

Atopic Dermatitis

1 drug in this indication

Genital Neoplasms, Female

1 drug in this indication

Medullary Thyroid Cancer

1 drug in this indication

ulcerative colitis, Crohn's disease

1 drug in this indication

Ulcerative colitis and Crohn's disease

1 drug in this indication

Platinum-sensitive ovarian cancer (FRα-targeting ADC, in combination with bevacizumab)

1 drug in this indication

Osteoporosis, Postmenopausal

1 drug in this indication

Recurrent Glioblastoma

1 drug in this indication

RET-altered metastatic thyroid cancer or solid tumors in pediatric patients two years of age and older

1 drug in this indication

Obesity-related heart failure

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Eli Lilly and Company's drug pipeline?→

CatalystAlert tracks 384 drug candidates in Eli Lilly and Company's (LLY) pipeline across Phase 3, Phase 2. Its lead program is Abemaciclib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Eli Lilly and Company's next FDA catalyst?→

Eli Lilly and Company's (LLY) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track LLY biotech catalysts?→

Add LLY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eli Lilly and Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply